Blockade of MMP-9 activity with andecaliximab, an anti-MMP-9 antibody, inhibits TGF-β1-induced SMAD2 phosphorylation in IPF patients who have sufficient type 1 IFN expression [170]. Here, MMP9 is linked to idiopathic pulmonary fibrosis.